ClinicalTrials.gg
Not yet recruitingNCT07309159F_r_IEND-3Updated Mar 16, 2026

Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study

A Phase 1/2 interventional study of Ecological Momentary Assessment (EMA) and Reality Monitoring tasks in Schizophrenia, sponsored by Centre Hospitalier Charles Perrens, Bordeaux. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Centre Hospitalier Charles Perrens, Bordeaux · Phase 1/2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to examine the dual effects of cannabis consumption on both positive and negative symptoms of schizophrenia, across laboratory and real-world contexts. By integrating ecological momentary assessment (EMA) with cognitive tasks such as reality monitoring, the research seeks to clarify how cannabis use influences symptom severity and cognitive functioning in individuals with schizophrenia. Gaining insight into these relationships may contribute to the development of more effective management strategies and ultimately improve outcomes for patients living with schizophrenia.

Read the detailed description

Schizophrenia is a complex psychiatric disorder that affects approximately 1% of the general population, typically emerging in early adulthood. It is characterized by a wide range of symptoms, including positive symptoms (e.g., hallucinations and delusions), negative symptoms (e.g., apathy and emotional blunting), and cognitive impairments. The disorder contributes substantially to the global burden of disease, ranking among the top 30 causes of disability-adjusted life years.

Cannabis use is common among individuals with schizophrenia, with estimates suggesting that between 16% and 42% of patients have used cannabis at some point in their lives. The relationship between cannabis use and schizophrenia is multifactorial. Cannabis consumption has been associated with an increased risk of psychosis, worsening of positive symptoms, and earlier onset of the disorder. However, some studies indicate that cannabis may also exert beneficial effects on negative symptoms, potentially mediated by compounds other than THC.

Cognitive deficits are a core feature of schizophrenia, particularly impairments in reality monitoring. Reality monitoring refers to the ability to distinguish between internally generated events (intrinsic) and those originating from external sources (extrinsic). In schizophrenia, this capacity is often compromised, leading to misattributions of internal thoughts to external sources, which may contribute to the development of positive symptoms such as hallucinations.

Given the dynamic nature of symptoms and substance use in schizophrenia, traditional clinical models may fail to capture the complexity of these interactions. Ecological Momentary Assessment (EMA) provides a novel approach by leveraging mobile devices to collect real-time data on symptoms, substance use, and cognitive performance in everyday life. EMA has been validated in schizophrenia research, offering high-resolution data that can complement and enhance traditional models.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • cannabis
  • schizophrenia
  • EMA
  • reality monitoring
03

In context

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's planned enrollment of 120 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Centre Hospitalier Charles Perrens, Bordeaux is the lead sponsor of 19 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of schizophrenia or schizo-affective disorder with the following clinical features:

    • Clinically stable and in the residual (non-acute) phase of illness,
    • No change in antipsychotic treatment for at least 1 month,
    • Outpatient, ambulatory care,
    • No uncontrolled positive symptoms (assessed using PANSS)
  • Patients able to use a mobile phone.
  • Capacity and willingness to give .
  • Must be able to read, speak, and understand French
  • Patients subscribing to the French national medical insurance.
  • Patients under "curatelle" (partial guardianship) are eligible

Exclusion criteria

Exclusion Criteria:

Patient under "tutelle" (full legal guardianship).

  • Psychiatric comorbidities: autism, bipolar disorder.
  • Current criteria for any other substance use disorder except for nicotine use disorder.
  • Any medical condition hindering the study and/or use of the smartphone application.
  • Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….).
  • Pregnant or breastfeeding woman.
  • Patients who are not proficient in French.
  • Subject included in clinical and/or therapeutic experimentation in progress.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    "Cannabis user" group (SZ-CUD)

    Use of Ecological Momentary Assessment (EMA) and a mobile Reality Monitoring task

    Other: Ecological Momentary Assessment (EMA) and Reality Monitoring tasks

  • Active comparator
    "Non-cannabis user" group (SZ-noCUD)

    Use of Ecological Momentary Assessment (EMA) and a mobile Reality Monitoring task

    Other: Ecological Momentary Assessment (EMA) and Reality Monitoring tasks

Interventions

  • OtherEcological Momentary Assessment (EMA) and Reality Monitoring tasks

    Use of Ecological Momentary Assessment (EMA) and a mobile Reality Monitoring task

06

What researchers measure

Primary outcomes

  1. Presence of a statistically significant association between cannabis consumption and the reduction of negative symptoms

    Presence of a statistically significant association between cannabis consumption and the exacerbation of positive symptoms with EMA scale

    Time frame: 8 days

  2. Presence of a statistically significant association between cannabis consumption and the exacerbation of positive symptoms

    Presence of a statistically significant association between cannabis consumption and the reduction of negative symptoms with EMA scale

    Time frame: 8 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Argote M, Sescousse G, Brunelin J, Baudin G, Schaub MP, Rabin R, Schnell T, Ringen PA, Andreassen OA, Addington JM, Brambilla P, Delvecchio G, Bechdolf A, Wobrock T, Schneider-Axmann T, Herzig D, Mohr C, Vila-Badia R, Rodie JU, Mallet J, Ricci V, Martinotti G, Knizkova K, Rodriguez M, Cookey J, Tibbo P, Scheffler F, Asmal L, Garcia-Rizo C, Amoretti S, Huber C, Thibeau H, Kline E, Fakra E, Jardri R, Nourredine M, Rolland B. Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals. EClinicalMedicine. 2023 Sep 8;64:102199. doi: 10.1016/j.eclinm.2023.102199. eCollection 2023 Oct. PubMed 37731936 ↗
  • Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007 Apr;115(4):304-9. doi: 10.1111/j.1600-0447.2006.00900.x. PubMed 17355521 ↗
  • Abdel-Baki A, Lal S, D-Charron O, Stip E, Kara N. Understanding access and use of technology among youth with first-episode psychosis to inform the development of technology-enabled therapeutic interventions. Early Interv Psychiatry. 2017 Feb;11(1):72-76. doi: 10.1111/eip.12250. Epub 2015 May 22. PubMed 26011657 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 30, 2025
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309159
Lead sponsor
Centre Hospitalier Charles Perrens, Bordeaux
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

David MISDRAHI, MD
Contact
dmisdrahi@ch-perrens.fr
+33 (0)5 56 56 34 49
David MISDRAHI, MD
study director · Centre Hospitalier Charles Perrens

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion